Yahoo Finance

Personal wellness company WeightWatchers (NASDAQ:WW) reported Q4 CY2024 results topping the market’s revenue expectations , but sales fell by 10.5% year on year to $184.4 million. Its non-GAAP profit of $0.32 per share was significantly above analysts’ consensus estimates.

Is now the time to buy WW? Find out in our full research report (it’s free).

WeightWatchers (WW) Q4 CY2024 Highlights:

• Revenue: $184.4 million vs analyst estimates of $175.7 million (10.5% year-on-year decline, 5% beat)

• Adjusted EPS: $0.32 vs analyst estimates of $0.07 (significant beat)

• Adjusted EBITDA: $49.74 million vs analyst estimates of $46.36 million (27% margin, 7.3% beat)

• Operating Margin: 19.6%, up from -2.9% in the same quarter last year

• Free Cash Flow Margin: 2.4%, down from 3.6% in the same quarter last year

• Members: 3.34 million, down 462,000 year on year

• Market Capitalization: $22.56 million

StockStory’s Take

WeightWatchers’ Q4 results reflected the ongoing transformation in the weight management industry, as the company navigates both subscriber declines and rapid changes in consumer preferences. Management attributed the quarter’s performance to continued headwinds in its traditional behavioral business, partially offset by robust growth in its clinical segment, which benefited from new offerings and improved access to weight loss medications. CEO Tara Comonte noted, “We’re focused on stabilizing and rebuilding for long-term sustainable growth,” highlighting recent product updates and operational changes as leading indicators of future momentum.

Looking ahead, management’s forward guidance centers on stabilizing the subscriber base, integrating clinical and behavioral programs, and addressing challenges related to medication supply and competitive marketing. The company emphasized the need for disciplined investment given high interest expenses and signaled that 2025 will be a year of resetting expectations. Comonte acknowledged, “Transformations take time and they take investments,” while CFO Felicia DellaFortuna stated that ongoing cost controls and product enhancements are expected to help position WeightWatchers for gradual recovery.

Key Insights from Management’s Remarks

WeightWatchers’ leadership focused on the dual challenge of declining traditional subscribers and growing clinical offerings. The company’s fourth quarter was shaped by new product features, deeper integration of its clinical business, and ongoing cost restructuring as it adapts to a changing competitive landscape and evolving consumer demand.

• Clinical segment momentum: Clinical subscriber growth accelerated, driven by improved access to weight loss medication and the addition of generic and compounded options. Management highlighted that clinical members deliver higher lifetime value and retention rates, and that expanding this business remains a top priority.

• Product innovation deployment: Several new features were launched, including an AI-powered food scanner, a recipe importer, and macro nutrient tracking. Management reported these updates have led to higher member engagement and reactivation, particularly among previously inactive users.

• Behavioral business pressure: The traditional behavioral business continued to experience recruitment and retention challenges, with management citing ongoing competitive pressures and shifting consumer preferences toward medication-assisted solutions.

• Cost reduction efforts: The company has actioned the majority of its $100 million run-rate cost savings target, resulting in increased operating margins and a leaner cost structure. Further operational reviews and AI-driven automation are planned to unlock additional efficiencies.

• Capital structure constraints: High debt levels and annual interest obligations are limiting the ability to invest aggressively in growth initiatives. Management has engaged advisors to explore options for improving financial flexibility and noted that the balance sheet will remain a key constraint in the near term.